Switching from allopurinol to febuxostat: Efficacy and tolerability in hemodialysis patients

被引:8
作者
Mitsuboshi S. [1 ]
Yamada H. [1 ]
Nagai K. [1 ]
Okajima H. [2 ]
机构
[1] Department of Pharmacy, Kaetsu Hospital, 1459-1 Higashikanazawa, Akiha-ku, Niigata-shi, Niigata
[2] Department of Internal Medicine, Kaetsu Hospital, 1459-1 Higashikanazawa, Akiha-ku, Niigata-shi, Niigata
关键词
Allopurinol; Febuxostat; Hemodialysis; Uric acid;
D O I
10.1186/s40780-015-0028-1
中图分类号
学科分类号
摘要
Background: Febuxostat is a novel xanthine oxidase inhibitor. However, few studies have examined the long-term efficacy and tolerability of febuxostat after switching from allopurinol in hemodialysis (HD) patients. Therefore, the present study evaluated the long-term efficacy and tolerability of febuxostat in HD patients after switching from allopurinol. Findings: We monitored the levels of hemoglobin, hematocrit, platelet count, blood urea nitrogen, serum creatinine, serum sodium, serum potassium, serum chloride, serum calcium, serum inorganic phosphorus, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, and total protein that were considered overall as a tolerability index, while the serum uric acid (UA) level was considered an index of efficacy. All values were measured at baseline and at 1, 6, 12, and 16 months after the switch to febuxostat therapy. All subjects switched from allopurinol (100 mg/day) to febuxostat (10 mg/day) in August 2013. Clinical laboratory data were collected at baseline in July 2013 until December 2014. Nine patients were included in the study analysis. Results showed that clinical laboratory data at baseline versus those at 16 months were not significantly different. Serum UA levels, which represented the efficacy index, were significantly different between the baseline level (6.8 ± 1.4) and those at 1, 6, 12, and 16 months (5.2 ± 1.1, 5.1 ± 1.1, 4.6 ± 0.9, and 5.4 ± 1.8 mg/dL, respectively; all p < 0.05). Conclusion: Switching from allopurinol to febuxostat in HD patients reduced serum UA levels, with no changes in other clinical laboratory data in the long term. © 2015 Mitsuboshi et al.
引用
收藏
相关论文
共 15 条
  • [1] Johnson R.J., Kang D.H., Feig D., Kivlighn S., Kanellis J., Watanabe S., Et al., Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?, Hypertension, 41, pp. 1183-1190, (2003)
  • [2] Cheung A.K., Sarnak M.J., Yan G., Berkoben M., Heyka R., Kaufman A., Et al., HEMO Study Group Cardiac disease in maintenance hemodialysis patients: result of the HEMO study, Kidney Int, 65, pp. 2380-2389, (2004)
  • [3] Thurston M.M., Phillips B.B., Bourg C.A., Safety and efficacy of allopurinol in chronic kidney disease, Ann Pharmacother, 47, pp. 1507-1516, (2013)
  • [4] Grabowski B.A., Khosravan R., Vernillet L., Mulford D.J., Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects, J Clin Pharmacol, 51, pp. 189-201, (2011)
  • [5] Faruque L.I., Ehteshami-Afshar A., Wiebe N., Tjosvold L., Homik J., Tonelli M., A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout, Semin Arthritis Rheum, 43, pp. 367-375, (2013)
  • [6] Castrejon I., Toledano E., Rosario M.P., Loza E., Perez-Ruiz F., Carmona L., Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis, Rheumatol Int, 35, pp. 1127-1137, (2015)
  • [7] Day R.O., Miners J.O., Birkett D.J., Whitehead A., Naidoo D., Hayes J., Et al., Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion, Br J Clin Pharmacol, 26, pp. 423-428, (1988)
  • [8] Akimoto T., Morishita Y., Ito C., Iimura O., Tsunematsu S., Watanabe Y., Et al., Febuxostat for hyperuricemia in patients with advanced chronic kidney disease, Drug Target Insights, 13, pp. 39-43, (2014)
  • [9] Tsuruta Y., Mochizuki T., Moriyama T., Itabashi M., Takei T., Tsuchiya K., Et al., Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease, Clin Rheumatol, 33, pp. 1643-1648, (2014)
  • [10] Kobayashi S., Ogura M., Hosoya T., Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease, J Clin Pharm Ther, 33, pp. 258-261, (2013)